Clinical trial of pemetrexed injection combinded with cisplatin injection in the treatment of recurrent lung adenocarcinoma
10.13699/j.cnki.1001-6821.2017.12.002
- VernacularTitle:培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究
- Author:
Hong CHEN
1
;
Xiao-Hong ZHOU
;
Guo-Quan LU
;
Ti-Ti ZHANG
Author Information
1. 安顺市人民医院肿瘤科
- Keywords:
pemetrexed injection;
cisplatin injection;
recurrent lung adenocarcinoma;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(12):1079-1081
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of pemetrexed injection combined with cisplatin injection in the treatment of recurrent lung adenocarcinoma.Methods A total of 80 patients with recurrent lung adenocarcinoma were randomly divided into control group (n =40 cases) and treatment group (n =40 cases).Control group was given docetaxel 75 mg · m-2,intravenous infusion for 1 h at day 1 + cisplatin 25 mg · m-2,intravenous infusion for 1 h at day 1-3.Treatment group was given pemetrexed 500 mg · m-2,intravenous infusion at day 1 + cisplatin 25 mg · m-2,intravenous infusion for 1 h at day 1-3.Two groups were treated for 2 cycles with 21 d per cycle.The clinical efficacy,survival time and adverse drug reactions were compared between two groups.Results After treatment,in the treatment and control groups,the overall response rates were 57.50％ (23/40 cases) and 47.50％ (19/40 cases),the disease control rates were 87.50％ (35/40 cases) and 77.50％ (31/40 cases)with significant difference (P ＜ 0.05).After treatment,in the treatment and control groups,the median progression-free survival were 6.4 and 5.8 months;the median overall survival time were 9.9 and 9.0 months;1 year survival rates were 35.00％ (14/40 cases) and 30.00％ (12/40 cases) without significant difference (P ＞ 0.05).The adverse drug reactions in treatment and control groups were based on leukopenia (50.00％ vs 47.50％),thrombocytopenia (7.50％ vs 10.00％),hemoglobin reduction (37.50％ vs 37.50％),nausea and vomiting (52.50％ vs 52.50％),hair loss (47.50％ vs 47.50％),liver and kidney injury (7.50％ vs 7.50％),the differences were not statistically significant (P ＞ 0.05).Conclusion Pemetrexed injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of recurrent lung adenocarcinoma,without increasing the incidence of adverse drug reactions.
